J(
Therapeutic Areas
Axogen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Avance® Nerve Graft | Peripheral nerve repair (gaps 5-70mm) | Approved |
| Axoguard® Nerve Connector | Tubular connection for nerve coaptation | Approved |
| Axoguard® Nerve Protector | Protection of nerve repairs and decompressions | Approved |
| Axoguard® HA+ Nerve Protector | Nerve protection with hyaluronic acid coating | Approved |
| Avive+® Soft Tissue Membrane | Soft tissue repair and reinforcement | Approved |
| Axoguard® Nerve Cap | Management of symptomatic neuromas | Approved |
Leadership Team at Axogen
MD
Michael Dale
President, Chief Executive Officer and Board Director
MB
Marc Began
Executive Vice President and General Counsel
LH
Lindsey Hartley
Chief Financial Officer
ED
Erick DeVinney
Chief Innovation Officer
JS
Jens Schroeder Kemp
Chief Marketing Officer
ID
Ivica Ducic, M.D., PhD
Chief Medical Officer
CS
Craig Swandal
Vice President, Operations
SA
Stacy Arnold
Vice President of Product Development and Clinical Research
AJ
Al Jacks
Vice President of Quality
DQ
Doris Quackenbush
Vice President of Sales